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Abstract
Endoplasmic reticulum (ER) stress and inflammation are important mechanisms that underlie
many of the serious consequences of type II diabetes. However, the role of ER stress and
inflammation in impaired ischaemia-induced neovascularization in type II diabetes is unknown.
We studied ischaemia-induced neovascularization in the hind-limb of 4-week-old db−/db− mice
and their controls treated with or without the ER stress inhibitor (tauroursodeoxycholic acid,
TUDCA, 150 mg/kg per day) and interleukin-1 receptor antagonist (anakinra, 0.5 μg/mouse per
day) for 4 weeks. Blood pressure was similar in all groups of mice. Blood glucose, insulin levels,
and body weight were reduced in db−/db− mice treated with TUDCA. Increased cholesterol and
reduced adiponectin in db−/db− mice were restored by TUDCA and anakinra treatment. ER stress
and inflammation in the ischaemic hind-limb in db−/db− mice were attenuated by TUDCA and
anakinra treatment. Ischaemia-induced neovascularization and blood flow recovery were
significantly reduced in db−/db− mice compared to control. Interestingly, neovascularization and
blood flow recovery were restored in db−/db− mice treated with TUDCA or anakinra compared to
non-treated db−/db− mice. TUDCA and anakinra enhanced eNOS-cGMP, VEGFR2, and reduced
ERK1/2 MAP-kinase signalling, while endothelial progenitor cell number was similar in all
groups of mice. Our findings demonstrate that the inhibition of ER stress and inflammation
prevents impaired ischaemia-induced neovascularization in type II diabetic mice. Thus, ER stress
and inflammation could be potential targets for a novel therapeutic approach to prevent impaired
ischaemia-induced vascular pathology in type II diabetes.
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Introduction
Neovascularization, a process that remodels pre-existing capillaries and forms new vessels,
is an essential component of recovery from ischaemic conditions [1]. Thus, the induction of
neovascularization is a critical event in the treatment of chronic tissue ischaemia seen in
peripheral vascular disease [2]. The induction of neovascularization has been reported to
involve a variety of factors that include cell therapy, intermediate signalling, and growth
factors [3–5]. Impaired neovascularization is still a major problem in patients with diabetes
and cardiac and peripheral vascular diseases [6–10]. The mechanism underlying the defect
in neovascularization is still unclear. Thus, a better understanding of the mechanism that
enhances neovascularization will greatly facilitate the development of therapeutic strategies
to protect tissues from chronic ischaemia.
Recent research has shown that endoplasmic reticulum (ER) stress and inflammation play an
important role in the aetiology of type II diabetes [1,11,12]. ER stress causes a complex
adaptive signalling response, defined as the unfolded protein response, and is involved in
several patho-physiological events. Inflammation is characterized by the presence of a
number of inflammatory molecules, including interleukin-1 (IL-1) [13,14]. IL-1 exerts its
effect by binding to the IL-1 type 1 receptor. It is well established that high IL-1 levels are
correlated with cardiovascular and metabolic diseases [15,16].
The importance of ER stress and inflammation in impaired ischaemia-induced
neovascularization, and blood flow recovery in type II diabetes is unknown. It is uncertain
whether ER stress and inflammation are related and act together to impair ischaemia-
induced neovascularization. Therefore, we tested the hypothesis that the inhibition of ER
stress and inflammation could prevent impaired ischaemia-induced neovascularization in a
mouse model of type II diabetes by up-regulating the angiogenic factors (NO–cGMP
pathway, VEGFR2) and reducing the anti-angiogenic factor (ERK1/2 MAP-kinase).
Materials and methods
Animal model and surgery
Four-week-old type 2 diabetic (db−/db−) mice and their wild-type db−/db+ (control) mice
(C57BL/6C genetic background) were used in the present study. The reasoning for the use
of these mice at such a young age was that at 4 weeks old these mice are not yet diabetic and
our goal was to prevent impaired ischaemia-induced neovascularization that occurs in adult
db−/db− mice. These studies conformed to the principles of the National Institutes of Health
‘Guide for the Care and Use of Laboratory Animals’ and were approved by the Tulane
University Institutional Animal Care and Use Committee. The hind-limb ischaemia
procedure was performed in all mice by ligation of the proximal segment of the right
femoral artery, as previously described [6,17,18].
Treatment
Four-week-old db−/db− mice (with normal blood glucose) were treated with the ER stress
inhibitor (tauroursodeoxycholic acid, TUDCA, 150 mg/kg per day, daily by intraperitoneal
injection) [19,20] or IL-1 receptor antagonist (anakinra, 0.5 μg/kg per day, daily by
intraperitoneal injection) just after surgery for 4 weeks.
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Blood glucose
Blood glucose measurements were obtained from tail vein samples using a blood glucose
meter (Prestige Smart System HDI; Home Diagnostics, Inc, Fort Lauderdale, FL, USA)
once a week in all groups after a 6 h fast [6,21].
Insulin level
The insulin level was determined at the end of treatment using the Mercodia Ultrasensitive
Mouse Insulin ELISA protocol (enzyme immunoassay; Mercodia AB, Uppsala, Sweden),
which estimates steady-state insulin resistance [6].
Cholesterol, adiponectin, and CRP
The plasma cholesterol level was measured using a cholesterol assay kit (Cayman Chemical
Company, Ann Arbor, MI, USA), while the plasma levels of CRP and adiponectin were
measured using Milliplex™ MAP Luminex MAP™ Technology (Billerica, MA, USA).
Blood pressure
Systolic blood pressure (SBP) was measured by tail-cuff plethysmography (BP-98A;
Softron, Tokyo, Japan) at the end of the treatment [22]. All mice were trained for tail cuff
measurement 1 week before starting the experiments. Measurements were performed at the
same time, always at 10 am, with the same number of measurements (ten times) for a single
measurement. The temperature at the time of measurement was the same for all groups of
mice.
Laser Doppler measurement of hind-limb blood flow
Each mouse was warmed to a core temperature of 37 °C and then hind-limb blood flow
measurements were performed over the region of interest (right and left limbs) before and
immediately after surgery, and serially over the 4-week period, with laser Doppler perfusion
imaging (LDPI) (Moor Instruments, Axminster, Devon, UK) [6].
X-ray quantification of hind-limb angiogenesis
Vessel density (all vessels of the ischaemic hind-limb) was assessed by high-definition
microangiography at the end of the treatment period, as previously described [6,23]. Data
are represented as per cent change, with ischaemic hind-limb values from control mice as
100%.
Western blot analysis
Western blot analysis of muscle of the hind-limbs was performed as previously described
[21,24,25]. The quantification of western blot was determined using Fujifilm-Multi Gauge
software. Specific antibodies for total eNOS, phosphorylated eNOS, total VEGFR2,
phosphorylated VEGFR2, CD31, and α-actin were purchased from Cell Signaling
Technology (Danvers, MA, USA). Specific antibodies for total and phosphorylated ERK1/2
MAP-kinase were purchased from Promega (Madison, WI, USA), while phosphorylated C-
JNK and MEK were purchased from Cell Signaling Technology.
Real-time RT-PCR
The mRNA levels of ER stress markers such as C/EBP homologous protein (CHOP) and
activating transcription factor 4 (ATF4) were determined in ischaemic hind-limbs from all
groups. Total RNA was obtained using the RNeasy Fibrous Tissue Mini Kit (Qiagen,
Valencia, CA, USA) according to the manufacturer’s recommendations. A total of 1 μg of
DNase I-treated RNA reverse was transcribed into cDNA using the High Capacity cDNA
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Archive Kit (Applied Biosystems, Foster City, CA, USA) with random hexamers in a 20 μl
reaction. PCR was performed in duplicate for each sample using 1 μl of cDNA as a
template, 1× TaqMan Universal PCR Master Mix (Applied Biosys-tems), and 10× Taqman
Gene Expression Assays (Applied Biosystems) in a 20 μl reaction. Assays-on-Demand
(Applied Biosystems) of TaqMan fluorescent real-time PCR primers and probes were used
for CHOP (Mm00492097_m1), ATF4 (Mm00515324_m1), and 18S rRNA
(Hs99999901_s1), which was used as an endogenous control to normalize the results.
Quantitative RT-PCR was carried out in an ABI PRISM 7000 Sequence Detection System
(Applied Biosystems) using the following conditions: 2 min at 50 °C, 10 min at 95 °C,
followed by 40 cycles of 15 s at 95 °C and 1 min at 60 °C. Relative mRNA levels were
determined using the 2−ΔΔCt method. Results are expressed as the relative expression of
mRNA in treated mice compared with untreated mice.
Colorimetric determination of cyclic guanyl-monophosphate (cGMP)
cGMP levels were measured in hind-limb muscles in all groups. We sacrificed mice and
immediately harvested and froze the hind-limb muscles in liquid nitrogen. Measurements
were performed using a sandwich enzyme-linked immunosorbent assay (ELISA; Cayman
Chemical Company) according to the manufacturer’s instructions and as previously
described [26,27].
Immunohistochemistry
Immumohistochemistry for endothelial and smooth muscle cells (CD31 and α-actin) and
inflammation (macrophage infiltration) was performed as previously described [10,21,25].
Endothelial progenitor cells (EPCs)
EPCs were isolated from bone marrow as previously described [28]. Mice were sacrificed
and bone marrow was harvested into a Petri dish. Bone marrow cells were centrifuged for 15
min at 15 000 rpm at 4 °C. Cells were then re-suspended in red blood cell lysis buffer and
centrifuged for 15 min at 15 000 rpm at 4 °C. Cells were then incubated with specific EPC
antibodies and the number of EPCs was determined using flow cytometry.
Statistical analysis
Results are expressed as mean ± SEM. One-way or two-way ANOVA was used to compare
each parameter when there were two independent groups. Comparisons between groups
were performed using post-hoc Bon-ferroni t-tests when the ANOVA test was statistically
significant. Values of p < 0.05 were considered significant. Differences between specified
groups were analysed using the Student’s t-test (two-tailed) for comparing two groups with
p < 0.05 considered statistically significant.
Results
Effect of ER stress and inflammation inhibition on blood pressure, body weight, blood
glucose, insulin, cholesterol, and adiponectin levels
At the end of the treatment period, we measured systolic blood pressure, which was similar
in all groups of mice (Figure 1A). Body weight and blood glucose levels were measured
once a week for 4 weeks. The results revealed that mice treated with TUDCA displayed a
significant reduction in body weight and a normalization of blood glucose and insulin levels
(Figures 1B–1D), while anakinra (Ana) treatment did not affect blood glucose and insulin
levels or body weight (Figures 1B–1D). Blood cholesterol levels were increased, while
adiponectin levels were reduced in db−/db− mice compared with control mice (Figures 1E
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and 1F). The treatment of db−/db− mice with TUDCA and Ana normalized cholesterol and
adiponectin levels compared with control mice (Figures 1E and 1F).
Effect of ER stress and inflammation inhibition on ER stress markers and macrophage
infiltration
Four weeks after femoral artery ligation, the mice were sacrificed and real-time RT-PCR
and immunostaining were performed in ischaemic hind-limb muscle from all groups to
determine the expression of ER stress markers and macrophage infiltration. Figure 2A
shows that ATF4 and CHOP mRNA levels were significantly increased in db−/db− mice
compared with control mice. The treatment of db−/db− mice with TUDCA and anakinra
significantly reduced ATF4 and CHOP mRNA. Macrophage infiltration was higher in db−/
db− mice compared with control and db−/db− mice treated with the ER stress inhibitor and
with anakinra (Figure 2B). These results were consistent with the increase in blood CRP
levels in db−/db− mice compared with control, which were reduced after TUDCA and Ana
treatment (Figure 2C).
Effect of ER stress and inflammation inhibition on blood flow
After surgery, blood flow was significantly reduced, in all groups of mice, to 5% of the
control value. Mice were then treated with TUDCA and anakinra for 4 weeks. Blood flow
recovery was measured once a week for a period of 4 weeks in all groups of mice. Our data
revealed that blood flow recovery was significantly blunted in the ischaemic hind-limb of db
−/db− mice compared with control mice (Figures 3A and 3B). Interestingly, TUDCA and
anakinra treatment significantly restored blood flow recovery in db−/db− mice compared
with non-treated db−/db− mice (Figures 3A and 3B).
To determine the relationship between ER stress, inflammation, and blood flow recovery in
type II diabetes, we performed the following experiments. Control mice were subjected to
femoral artery ligation and then injected with tunicamycin (ER stress activator) or IL-1 once
a week for 2 weeks. Figure 3C illustrates a significant reduction in blood flow recovery
(40%) in control mice with tunicamycin or IL-1 compared with untreated control mice
(100%). Importantly, when tunicamycin and IL-1 injections were stopped, blood flow
recovery was restored to 100% (Figure 3C).
Effect of ER stress and inflammation inhibition on vessel density
Vessel density was evaluated by high definition microangiography at the end of the
treatment period. After 4 weeks, vessel density was similar between the ischaemic (right)
and non-ischaemic (left) hind-limb in control mice (Figures 4A and 4B). However, in db−/
db− mice, the ischaemic hind-limb vessel density was significantly reduced compared with
the ischaemic hind-limb in control mice. Interestingly, vessel density was significantly
increased in the ischaemic hind-limb in db−/db− mice treated with TUDCA and anakinra
compared with untreated db−/db− mice (Figures 4A and 4B).
Effect of ER stress and inflammation inhibition on capillary density
Capillary density, determined by immunostaining with CD31 specific antibody, was
significantly reduced in db−/db− mice compared with control mice (Figure 5). The
inhibition of ER stress and inflammation induction significantly prevented the decrease in
capillary density in db−/db− mice (Figure 5).
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Effect of ER stress and inflammation inhibition on the cGMP, eNOS/VEGFR2/ERK1/2 MAP-
kinase pathway
VEGFR2, eNOS phosphorylation, and cGMP levels were significantly reduced, while
ERK1/2 MAP-kinase phosphorylation and expression were enhanced in the ischaemic hind-
limb of db−/db− mice compared with control (Figures 6A–6D). The inhibition of ER stress
and inflammation augmented VEGFR2 and eNOS phosphorylation and cGMP levels, and
reduced ERK1/2 phosphorylation and expression in db−/db− mice (Figures 6A–6D). We
also demonstrated that C-JNK and MEK phosphorylation was enhanced in db−/db− mice
compared with control and db−/db− mice treated with TUDCA and Ana (Figures 6E and
6F). Figures 6G and 6H illustrate a similar number of endothelial progenitor cells from bone
marrow in db−/db− and control mice.
Discussion
The adaptive growth of microvessels is a vital protective mechanism in ischaemia-induced
pathology. This adaptive process is impaired in type II diabetes [6,18,29] but the underlying
mechanism of impaired ischaemia-induced neovascularization is yet to be determined. We
have investigated the therapeutic efficacy of inhibition of endoplasmic reticulum (ER) stress
and inflammation on ischaemia-induced neovascularization in a preclinical model of
diabetic limb ischaemia.
In the present study, we observed impaired ischaemia-induced neovascularization, ER stress
induction, and inflammation subsequent to femoral artery ligation in db−/db− mice. We
observed that chronic ER stress inhibition and IL-1 receptor antagonism significantly
improved blood flow recovery, as evidenced by enhanced ischaemia-induced
neovascularization, vessel and capillary density, and up-regulated angiogenic factors
(eNOS–cGMP pathway and VEGFR2 phosphorylation). Endothelial progenitor cells were
considered to be important in angiogenesis as previously described [30]. Our results showed
that endothelial progenitor cell number was similar in db−/db− and control mice, suggesting
that these cells could express a defect in migration, adhesion, and differentiation in db−/db−
mice. The improvement in tissue perfusion was consistent with the reduction in MEK, C-
JNK, and ERK1/2 MAP-kinase phosphorylation. The inhibition of ER stress and
inflammation was assessed by the reduction in ER stress markers (CHOP and ATF4) and the
reduction in macrophage infiltration in the ischaemic hind-limb of db−/db− mice, and by the
CRP plasma levels.
It is well established that in type II diabetes, the most prevalent metabolic disease
worldwide, chronic inflammation contributes to insulin resistance [31]. Interleukin-1 has
been reported to play a role in the sustained inflammation observed in type II diabetes [32].
Interestingly, the antagonist of the interleukin-1 receptor (anakinra) was shown to alleviate
symptoms in neonatal-onset multisystem inflammatory disease [32]. In our study, systolic
arterial blood pressure was similar in all groups, indicating that db−/db− mice are
normotensive [21] and that treatment did not affect blood pressure. Interestingly, blood
glucose and insulin levels, and body weight were significantly reduced in db−/db− mice
treated with TUDCA, but not with anakinra. These data suggest that insulin resistance,
hyperglycaemia, and obesity are modulated by the endoplasmic reticulum but not by
interleukin-1 expression. In terms of ER stress, our data are in agreement with previous
studies showing that inhibition of ER stress reduced the onset of type II diabetes [19,20]. In
terms of the effect of the interleukin-1 receptor antagonist, our data are not in agreement
with previous studies showing that anakinra treatment improved blood glucose and insulin
levels in patients with type II diabetes [32]. The treatment with anakinra did not alter blood
glucose and insulin levels or body weight in the mice. This divergence in results could be
related to the use of very young db−/db− mice, and it remains to be determined if this
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mechanism also exists in older db−/db− mice and in other models of type II diabetes.
TUDCA reduced ER stress markers in db−/db− mice and surprisingly, anakinra also reduced
ER stress markers. However, further studies are needed to delineate the mechanism that
relates inflammation to ER stress.
It is important to mention that there is a difference in effect between TUDCA and anakinra
in terms of blood glucose and insulin levels, and body weight regulation. The reductions in
ER stress markers and enhanced blood flow recovery were similar in db−/db− mice treated
with TUDCA or anakinra. These data suggest that ER stress has an important role in
regulating blood glucose and insulin levels, and body weight, while interleukin-1 augmented
blood flow recovery is independent of an effect on blood glucose and insulin levels, and
body weight. The results showing that cholesterol, adiponectin, and CRP levels were
restored after treatment with TUDCA suggested that metabolic function in adipose tissue
and the liver is improved.
To refine our insight into the link between ER stress, inflammation, and blood flow recovery
in type II diabetes, control mice were subjected to femoral artery ligation and then locally
injected with tunicamycin (ER stress activator) or IL-1 once a week for 4 weeks. These
results show a significant reduction in blood flow recovery (40%) in control mice with
tunicamycin and IL-1 treatment compared with untreated control mice (100%). Importantly,
when the tunicamycin and IL-1 treatment was stopped, blood flow recovery was restored to
100%. These data clearly indicate that ER stress and IL-1 are important factors in the
impaired ischaemia-induced neovascularization that occurs in type II diabetes. Thus, ER
stress and inflammation could be potential targets for therapeutic interventions to reduce
ischaemia-induced vascular pathology in type II diabetic patients.
The global prevalence of diabetes is predicted to almost double by the year 2030 from 2.8%
to 4.4%. In individuals with diabetes, a significant number of patients will develop lower
extremity disease including peripheral neuropathy, foot ulcers, and peripheral arterial
disease (PAD), which is a high risk for heart attack and stroke. There is therefore a
significant medical need to develop novel therapies to increase the formation of new vessels,
especially in patients with type II diabetes. In the present study, we delineated the
mechanism responsible for the impaired ischaemia-induced neo-vascularization in type II
diabetes, which involves ER stress and inflammation. Our results demonstrated that ER
stress and inflammation have differential effects on blood glucose and insulin levels.
Although the mechanisms of ER stress and inflammation in type II diabetes are unknown,
ER stress and inflammation could be potential targets for therapy to treat vascular occlusive
diseases by promoting the formation of new vessels and therefore protecting tissue from
ischaemia-induced vascular pathology.
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Figure 1.
(A) Systolic arterial blood pressure in all groups measured by the tail cuff methods. n = 7.
(B) Body weight in control (CTR) and db−/db− mice treated with and without TUDCA
(TUD) and anakinra (Ana). n = 7. *p < 0.05 for CTR versus db−/db−; #p < 0.05 for db−/db−
versus db−/db− treated with TUDCA. (C) Blood glucose levels in all groups. n = 7. *p <
0.05 for CTR and db−/db− mice treated with TUDCA versus db−/db− with and without
anakinra. (D) Insulin level in all groups. n = 7. *p < 0.05 for CTR and db−/db− treated with
TUDCA versus db−/db− with and without anakinra. (E) Cholesterol levels in all groups. n =
4. *p < 0.05 for db−/db− versus CTR, db−/db− + TUDCA and Ana. (F) Adiponectin levels
in all groups. n = 4. *p < 0.05 for db−/db− versus CTR, db−/db− + TUDCA and Ana.
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Figure 2.
(A) ATF4 and CHOP mRNA levels determined using real-time RT-PCR in ischaemic hind-
limb from all groups. n = 5. *p < 0.05 for db−/db− versus control (CTR) mice and db−/db−
mice with and without TUDCA and anakinra (Ana). (B) Immunostaining of macrophages in
the ischaemic hind-limb from all groups. (This figure is representative of n = 5.) (C) CRP
levels in all groups. n = 4. *p < 0.05 for db−/db− versus CTR, db−/db− + TUDCA and Ana.
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Figure 3.
(A) Blood flow recovery measured with a Moor LPDI laser in the ischaemic hind-limb of
control (CTR) and db−/db− mice with or without TUDCA and anakinra (Ana) before (Pre)
and after surgery, and once a week for 4 weeks. This picture is representative of n = 8. (B)
Quantitative data for blood flow recovery in all groups of mice. n = 8. *p < 0.05 for db−/db−
mice versus control (CTR) and db−/db− mice + TUDCA and anakinra (Ana). (C) Blood
flow recovery measured in ischaemic hind-limb of control (CTR) mice and CTR mice
locally injected with tunicamycin (TUN) for 4 weeks or interleukin-1 (IL-1) for 2 weeks. n =
4. *p < 0.05 for CTR versus CTR + TUN or IL-1.
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Figure 4.
(A) Microangiography performed at the end of the treatment in all groups of mice [control
(CTR), and db−/db− with and without TUDCA and anakinra (Ana)]. Contrast medium
(barium sulphate, 0.5 μg/ml) was injected into the abdominal aorta and angiography of the
right and left hind-limbs was assessed with digital X-ray-acquired images. Images were then
assembled to obtain a composite view of the hind-limb. The image is representative of n = 6.
(B) Quantitative data (score in %) showing ischaemic hind-limb vessel density using Multi
Gauge (Fujifilm) by selecting the same area for measurement in all groups. n = 6. *p < 0.05
for db−/db− mice versus control (CTR) and db−/db− mice + TUDCA and anakinra (Ana).
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Figure 5.
Example of immunostaining with specific antibodies for α-actin (red staining, white arrows)
and CD31 (green staining; capillaries). Yellow staining (yellow arrows) represents arterioles
which ‘merge between green and red’. Quantitative data of CD31 expression in all groups. n
= 5. *p < 0.05 for db−/db− mice versus control (CTR) and db−/db− mice + TUDCA and
anakinra (Ana).
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Figure 6.
Western blot analysis and quantitative data showing total (T) and phosphorylated (P) eNOS
in the ischaemic hind-limb from all groups (A); total (T) and phosphorylated (P) VEGFR2
in ischaemic hind-limb from all groups (B); and total (T) and phosphorylated (P) ERK1/2
MAP-kinase in ischaemic hind-limb from all groups (D). n = 6. *p < 0.05 for db−/db− mice
versus control (CTR) and db−/db− mice + TUDCA and anakinra (Ana). (C) cGMP levels in
ischaemic hind-limb from all groups. n = 6. *p < 0.05 for db−/db− mice versus control
(CTR) and db−/db− mice + TUDCA and anakinra (Ana). (E, F) Phosphorylated C-JNK (P-
C-JNK) and MEK (P-MEK) in ischaemic hind-limb in all groups of mice. (G, H) Flow
cytometry for EPCs in bone marrow from db−/db− and control mice.
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